FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 251 filers reported holding FATE THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.41 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $1,196,069 | -32.6% | 118,540 | +49.6% | 0.01% | -28.6% |
| Q3 2022 | $1,775,000 | -27.2% | 79,216 | -19.4% | 0.01% | -22.2% |
| Q2 2022 | $2,437,000 | -17.6% | 98,343 | +29.0% | 0.01% | 0.0% |
| Q1 2022 | $2,957,000 | -1.4% | 76,258 | +48.8% | 0.01% | 0.0% |
| Q4 2021 | $2,998,000 | +5.4% | 51,240 | +6.8% | 0.01% | 0.0% |
| Q3 2021 | $2,845,000 | -32.1% | 47,995 | -0.5% | 0.01% | -35.7% |
| Q2 2021 | $4,187,000 | +16.0% | 48,243 | +10.2% | 0.01% | +7.7% |
| Q1 2021 | $3,609,000 | -11.8% | 43,770 | -2.7% | 0.01% | -7.1% |
| Q4 2020 | $4,092,000 | +57.3% | 45,007 | -30.8% | 0.01% | +40.0% |
| Q3 2020 | $2,601,000 | +13.1% | 65,079 | -2.9% | 0.01% | 0.0% |
| Q2 2020 | $2,299,000 | +38.6% | 67,016 | -37.3% | 0.01% | +66.7% |
| Q3 2019 | $1,659,000 | – | 106,800 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $83,733,000 | 21.39% |
| Redmile Group, LLC | 12,957,222 | $321,080,000 | 12.26% |
| GCM Grosvenor Holdings, LLC | 1,037,256 | $25,703,000 | 5.81% |
| Casdin Capital, LLC | 2,100,000 | $52,038,000 | 4.40% |
| Ally Bridge Group (NY) LLC | 181,500 | $4,498,000 | 4.10% |
| DAFNA Capital Management LLC | 550,940 | $13,652,000 | 3.72% |
| Artal Group S.A. | 2,600,000 | $64,428,000 | 3.44% |
| Deep Track Capital, LP | 2,018,005 | $50,006,000 | 3.29% |
| HighVista Strategies LLC | 118,778 | $2,943,000 | 1.78% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 3,917 | $158,000,000 | 1.65% |